iScience (Feb 2023)

Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis

  • Miriam Magallón-Lorenz,
  • Ernest Terribas,
  • Sara Ortega-Bertran,
  • Edgar Creus-Bachiller,
  • Marco Fernández,
  • Gerard Requena,
  • Inma Rosas,
  • Helena Mazuelas,
  • Itziar Uriarte-Arrazola,
  • Alex Negro,
  • Tereza Lausová,
  • Elisabeth Castellanos,
  • Ignacio Blanco,
  • George DeVries,
  • Hiroyuki Kawashima,
  • Eric Legius,
  • Hilde Brems,
  • Viktor Mautner,
  • Lan Kluwe,
  • Nancy Ratner,
  • Margaret Wallace,
  • Juana Fernández-Rodriguez,
  • Conxi Lázaro,
  • Jonathan A. Fletcher,
  • David Reuss,
  • Meritxell Carrió,
  • Bernat Gel,
  • Eduard Serra

Journal volume & issue
Vol. 26, no. 2
p. 106096

Abstract

Read online

Summary: Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas of the peripheral nervous system that develop either sporadically or in the context of neurofibromatosis type 1 (NF1). MPNST diagnosis can be challenging and treatment outcomes are poor. We present here a resource consisting of the genomic characterization of 9 widely used human MPNST cell lines for their use in translational research. NF1-related cell lines recapitulated primary MPNST copy number profiles, exhibited NF1, CDKN2A, and SUZ12/EED tumor suppressor gene (TSG) inactivation, and presented no gain-of-function mutations. In contrast, sporadic cell lines collectively displayed different TSG inactivation patterns and presented kinase-activating mutations, fusion genes, altered mutational frequencies and COSMIC signatures, and different methylome-based classifications. Cell lines re-classified as melanomas and other sarcomas exhibited a different drug-treatment response. Deep genomic analysis, methylome-based classification, and cell-identity marker expression, challenged the identity of common MPNST cell lines, opening an opportunity to revise MPNST differential diagnosis.

Keywords